Preparation of [131I]lipiodol as a hepatoma therapeutic agent.
An isotopic exchange method was used to label lipiodol with 131I. The labelling efficiency was > 92.5%, and the radiochemical purity of [131I]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the heating temperature, reaction time, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [131I]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of alpha-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months).
Lo
J G
JG
Institute of Nuclear Science, National Tsing Hua University, Hsinchu, Taiwan, Republic of China.
Wang
A Y
AY
Wei
Y Y
YY
Lui
W Y
WY
Chi
C W
CW
Chan
W K
WK
D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007459:Iodized Oil / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007553:Isotope Labeling; D008113:Liver Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D010865:Pilot Projects
D007457:Iodine Radioisotopes; D007459:Iodized Oil